Leukemia Clinical Trials in California

Showing 561-580 of 1,010 trials

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

NCT01177540

The purpose of this study is to provide data on the activity of a standard daunorubicin, cytarabine, and etoposide (ADE) induction plus epigenetic priming with decitabine as assessed by standard measures of complete remission (CR), leukemia free survival (LFS) and overall survival (OS), as well as, on minimal residual disease (MRD). It will also provide necessary data on the safety and Pharmacokinetics (PK) of decitabine in pediatric patients that is currently unavailable.

Pediatric Acute Myelogenous Leukemia (AML)

Eisai Inc.25 participantsStarted Mar 2011

Phoenix, Arizona, United States • Madera, California, United States • Aurora, Colorado, United States +19 more locations

COMPLETEDPhase 363 miles

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

NCT02625610

The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

EMD Serono Research & Development Institute, Inc.499 participantsStarted Dec 2015

Bakersfield, California, United States • Fullerton, California, United States • Los Angeles, California, United States +197 more locations

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Leukemia Trials in Other Cities

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Other Conditions in California